ERIS Lifesciences Ltd's Q1FY19 consolidated net profit rises 1.08% yoy to Rs71.60cr: Misses Estimates

The company’s consolidated revenue stood at Rs250.76cr, up 35.39% yoy and 18.18% qoq.

Aug 09, 2018 02:08 IST India Infoline Research Team

ERIS Lifesciences Ltd Q1FY19

Consolidated Results Q1FY19: (Rs. in cr)

Q1FY19 YoY (%)
Revenue 250.76 35.4
EBITDA 88.55 24.0
EBITDA Margin (%) 35.3 [326]
Net Profit (adjusted) 71.60 1.1
***EBITDA margin change is bps

Eris Life’s revenue in Q1FY19 grew by 35.4% yoy to Rs250.8cr. EBITDA grew by 24% yoy to Rs88.6cr in Q1FY19 vs. Rs71.4cr in Q1FY18. EBITDA margins stood at 35.3% in Q1FY19 vs. 33.8% in Q4FY18 and 38.6% in Q1FY8. PAT grew by 1.1% yoy to Rs71.6cr in Q1FY19 vs. Rs70.8cr in Q1FY18 and Rs56.1cr in Q4FY18.
  • The numbers include inorganic growth due to the acquisition of the India business of Strides Shasun in Q3FY18.
  • Gross margins in Q1FY19 stood at 84.5% in Q1FY19 vs. 85.2% in Q1FY18. Sequentially, the gross margins have not shown any improvement.
  • PAT was impacted due to 37.7% yoy increase in employee cost, 46.6% yoy increase in other expenses, and higher depreciation from Strides Shasun’s acquired portfolio and interest expenses.

Technical View: 

ERIS Lifesciences Ltd is currently trading at Rs. 716, down by 33.05 points or 4.41% from its previous closing of Rs. 749.05 on the BSE.
The scrip opened at Rs. 732 and has touched a high and low of Rs. 737.15 and Rs. 712.05 respectively. So far 26,894 (NSE+BSE) shares were traded on the counter. The stock is currently trading above its 200 DMA.

Related Story